<DOC>
	<DOC>NCT00955409</DOC>
	<brief_summary>The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Subjects randomized under previous 3134K1200 study (NCT00479557) and met all inclusion/and none of the exclusion criteria Screening brain MRI scan is consistent with the diagnosis of AD ' MiniMental State Examination (MMSE) score =10 Significant Neurological Disease other than Alzheimer's disease Brain MRI evidence of vasogenic edema (VE) during the preceding 3134K1 200 study (NCT00479557) Clinically significant systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>